טוען...
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical stud...
שמור ב:
| הוצא לאור ב: | Pharmacol Res |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876767/ https://ncbi.nlm.nih.gov/pubmed/26995304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2016.03.013 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|